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Abstract: In idiopathic Parkinson´s disease (PD), a generalized Lewy body type-degeneration in the brain as well as ex-
tracranial organs was identified. It is unclear, whether cerebral and extracranial Lewy body type-degeneration in PD are 
coupled or not. To address this question, cerebral [
123I]FP-CIT SPECT – to quantify cerebral nigrostriatal dopaminergic 
degeneration – and myocardial [
123I]MIBG scintigraphy – to quantify extracranial myocardial sympathetic degeneration – 
were performed in 95 PD patients and 20 healthy controls. At each Hoehn and Yahr stage separately, myocardial MIBG 
uptake correlated significantly with striatal FP-CIT uptake. No such correlation was found in the controls. Cerebral and 
extracranial Lewy body type-degeneration in PD do not develop independently from each other but develop in a strongly 
coupled manner. Obviously cerebral and extracranial changes are driven by at least similar pathomechanisms. Our find-
ings in controls contradict a physiological correlation between nigrostriatal dopaminergic and myocardial sympathetic 
function. 
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INTRODUCTION 
  Idiopathic Parkinson´s disease (PD) results from a Lewy 
body type-degeneration of dopaminergic neurons in the pars 
compacta of substantia nigra. First parkinsonian motor 
symptoms occur after a loss of about 60 per cent of dopa-
minergic nigral cells and after dopamine concentration in the 
posterior putamen has been reduced by about 80 per cent 
(Bernheimer JCS 1973; Deuschl 1999) [1, 2]. This presynap-
tic nigrostriatal dopaminergic deficit in PD can be quantified 
by [
123I]FP-CIT SPECT. FP-CIT SPECT measures the con-
centration of presynaptic striatal dopamine reuptake trans-
porters (Booij Synapse 2001) [3]. Beyond the cerebral Lewy 
body type-degeneration, numerous studies found a Lewy 
body type-degeneration outside the brain in PD, too, primar-
ily in the extracranial autonomous nervous system (Edwards 
Neurology 1992, Iwanaga Neurology 1999, Kaufmann Neu-
rology 2004, Micieli NS 2003, Okada PI 2004, Wakabayashi 
EJ 1997) [4-9]. These studies show that PD does not affect 
only the brain. It is unclear, whether cerebral and extracra-
nial Lewy body type-degeneration in PD are coupled or not. 
 [
123I]MIBG scintigraphy measures the function of extrac-
ranial myocardial postganglionic sympathetic innervation. 
[
123I]MIBG is a radioiodinated analogue of noradrenaline 
(norepinephrine). It is actively transported into noradrenaline 
granules of sympathetic nerve terminals by the noradrenaline 
transporter (Wieland JNM 1980) [10]. [
123I]MIBG scintigra-
phy reveals a high sensitivity concerning PD because it dis-
closes an impaired myocardial postganglionic sympathetic 
innervation in PD (Braune CAR 2001, Hamada JNNP 2003, 
Yoshita NMC 1998) [11-13]. These data suggest that MIBG 
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scintigraphy allows estimating the extent of Lewy body type-
degeneration of the cardiac plexus, exemplarily of an extrac-
ranial structure. 
  Since there exists no information about the correlation 
between cerebral and extracranial Lewy body type-
degeneration in PD, we applied FP-CIT SPECT and MIBG 
scintigraphy to address this point in PD. We used FP-CIT 
SPECT/MIBG scintigraphy to quantify nigrostriatal dopa-
minergic/myocardial sympathetic degeneration. We looked 
for a correlation between cerebral nigrostriatal degeneration 
and extracranial myocardial sympathetic degeneration. Such 
a correlation would indicate that 1) cerebral nigrostriatal 
dopaminergic and extracranial myocardial sympathetic Lewy 
body type-degeneration are coupled and that 2) both degen-
erative processes result from identical or at least similar 
processes. Since stage, severity and duration of PD correlate 
significantly with reduction of nigrostriatal FP-CIT uptake 
(Benamer MD 2000) [14] and myocardial MIBG uptake 
(Hamada JNNP 2003) [12], we evaluated PD patients sepa-
rately after Hoehn and Yahr stage to exclude a statistical bias 
due to the factors disease stage or severity. 
PATIENTS AND METHODS 
Patients and controls 
Patients 
  The study involved 95 patients with idiopathic Parkin-
son´s disease (PD; age 59 ± 11 years, mean ± SD, further 
details in Table 1). PD was diagnosed according to the crite-
ria of the UK Parkinson´s Disease Society Brain Bank 
(Hughes JNNP 1992) [15]. Two different neurologists exam-
ined the patients. No patient was found to have a history of 
neuroleptic intake or other identifiable possible causes for 
secondary Parkinsonism. Cerebral MRI findings were nor-
mal in all patients, particularly regarding the absence of ei-2    The Open Neurology Journal, 2007, Volume 1  Spiegel et al. 
ther white matter lesions or ventricular widening. Therapy 
with selegiline was discontinued at least 18 hours before FP-
CIT application due to possible interaction of its metabolites 
with striatal FP-CIT binding (Laruelle Synapse 1993) [16]. 
Further antiparkinsonian medication was continued during 
the time of scintigraphic examinations. Aware of the prob-
lem facing FP-CIT SPECT and MIBG scintigraphy in pa-
tients treated with antiparkinsonian drugs, the present data 
(Ahlskog MD 1999, Guttman Neurology 2001, Innis MD 
1999, Laruelle Synapse 1993, Nurmi JCBFM 2000, Satoh 
JCN 1999, The Parkinson Study Group JAMA 2002) [16-22] 
did not allow a clear conclusion concerning the effect of do-
paminergic drugs, neither on dopamine transporter binding, 
nor on MIBG distribution. 
Table 1.  Demographic Data of Patients 
 
  H&Y 1   H&Y 2   H&Y 3+4 
N   63   12   20 
Females  27   3   11 
Males  36   9   9 
Age (range)  37 – 78    40 – 71    42 – 76 
Age  58 ± 10    56 ± 11   63 ± 8 
UPDRS part III  11 ± 2   18 ± 3   30 ± 9 
H&Y = Hoehn and Yahr stage (Hoehn Neurology 1967) [27]. No patient was at H&Y 
stage 5. Due to the case number of patients at H&Y stage 4 (n = 5) we combined the 
patients at H&Y stage 3 (n = 15) and H&Y stage 4 (n = 5) to one single group. N = 
number of patients. UPDRS part III = part III (motor part) of the Unified Parkinson´s 
disease rating scale (UPDRS, Fahn 1987) [28]. Antiparkinsonian medication had been 
stopped 12 hours before UPDRS scale was rated. Unless otherwise declared, all values 
are represented as mean ± SD. 
 
  20 subjects (9 females, 11 males, age 37 – 74 years, 57 ± 
11 years) underwent FP-CIT SPECT and MIBG scintigraphy 
because they were referred by the outpatient physician, who 
assumed a beginning PD. After PD had been excluded by 
clinical criteria and by the further clinical course, these sub-
jects served as controls for the correlation between FP-CIT 
SPECT and MIBG scintigraphy. 11 of these 20 subjects were 
suffering from essential tremor, 2 from psychogenic Parkin-
sonism, and 7 had no neurological or psychiatric disease. 
These controls were not significantly different from PD pa-
tients concerning age (p = 0.93; unpaired t-test). The norm 
values for FP-CIT SPECT and MIBG scintigraphy were not 
obtained from these controls but from other controls (see 
below). 
  In regard to the scintigraphic examinations, patients or 
controls with a clinical history of angina pectoris, arrhyth-
mia, myocardial infarct, hypothyroidism, diabetes mellitus, 
cerebrovascular events, psychiatric disorders (except psy-
chogenic Parkinsonism), malignancy, hypertension, phaeo-
chromocytoma or any other disease, that might affect uptake 
of myocardial [
123I]MIBG, were excluded. No subject was 
treated by tricyclic antidepressant drugs or other serotonin 
reuptake inhibitors, reserpine, clonidine, amphetamines, 
phenylpropanolamine, amiodarone or substances inducing 
any blockade of calcium channels. Written informed consent 
was obtained from all subjects prior to examination. The 
protocol was approved by the local ethics committee (Ethik-
kommission der Ärztekammer des Saarlandes). 
 
Data Acquisition 
[
123I]FP-CIT SPECT 
  Cerebral SPECT imaging was performed with iodine 123 
ioflupane (DaTscan
®, Amersham Cygne, Eindhoven, The 
Netherlands). 4 hours following thyroid gland blocking and 
intravenous injection of the radioactive substance (110 - 185 
MBq, specific activity: 580 - 1040 GBq/mg) cerebral SPECT 
images were obtained. A triple-head gamma camera (Sie-
mens Multispect, MS 3) equipped with low-energy high-
resolution collimators was used. Data was acquired in a 128 
x 128 matrix covering 120 degrees per camera and head, 50 
seconds per view. A total of 120 views was acquired. Energy 
discrimination was centered in 158 keV with a 15% window. 
Image filtering (Butterworth, Cutoff 0.5) was followed by 
attenuation correction (Chang, 0.11/cm). Registration and 
semiquantitative analysis were performed with a workstation 
(HERMES, Nuclear Diagnostics, Stockholm, Sweden) and a 
software named BRASS (Nuclear Diagnostics, Stockholm, 
Sweden), modified for this purpose. The caudate nucleus, 
putamen and occipital lobe binding of [
123I]FP-CIT was as-
sessed semiquantitatively by a regions of interest (ROI) 
technique and compared with a control group. The ROI´s 
included 524 pixels (according volume = 4.2 cm
3) for each 
caudate nucleus, 689 pixels (according volume = 5.5 cm
3) 
for each putamen, and 9008 pixels (according volume = 72 
cm
3) for both occipital cortices together. We regarded a 
small central area within each nucleus and did not consider 
the whole nucleus to avoid partial volume and resolution 
effects. We calculated the ratio caudate nucleus/occipital 
lobe binding and the ratio putamen/occipital lobe binding. 
Our norm values obtained from controls were previously 
described (Spiegel JNNT 2007) [23]. 
[
123I]MIBG Scintigraphy 
  In a time period of 4 to 7 days preceding or following 
FP-CIT SPECT of the brain, MIBG examination of the heart 
took place: Following thyroid gland blocking with sodium, 
perchlorate intravenous injection of [
123I]MIBG (Amersham, 
Amersham Buchler, Braunschweig, Germany) with a spe-
cific activity of 259 - 370 MBq/mg was given. The injected 
doses of MIBG ranged from 180 to 250 MBq. Planar whole-
body images in anterior and posterior views were obtained 4 
h after the injection using a dual-head large-field camera 
(Siemens Multispect, MS 2) equipped with low-energy high-
resolution parallel-hole collimators. MIBG uptake of myo-
cardium and mediastinum was quantified after drawing of a 
rectangular region of interest over the upper mediastinum 
and an irregularly configured region outlining the whole 
heart. Then the heart-to-mediastinum (H/M) count-ratio was 
calculated, which was defined as the average cts/pixel in the 
myocardium divided by that of the upper mediastinum. Our 
norm values obtained from controls were previously de-
scribed (Spiegel MD 2005) [24]. Within one day after MIBG 
imaging, additional myocardial rest perfusion imaging was 
performed afterwards with 
99mTc-Sestamibi (MIBI, Cardio-
lite
®, Bristol Myers Squibh, USA, 500 MBq). This perfusion 
imaging was used to exclude a myocardial hypoperfusion 
that may influence MIBG imaging adversely. Patients with 
an impaired myocardial perfusion were excluded from fur-
ther investigation. 
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Statistical Analysis 
  Correlations were calculated using the Pearson´s correla-
tion coefficient in case of a normally distributed data and 
Spearman´s correlation coefficient in case of a not normally 
distributed data. 
RESULTS 
Patients 
  At all Hoehn and Yahr stages, caudate nucleus (CN) and 
putamen (PUT) FP-CIT uptake contralateral to the clinically 
more affected body side ( = contralateral uptake) were sig-
nificantly smaller than CN/PUT FP-CIT uptake ipsilateral to 
the clinically more affected body side ( = ipsilateral uptake). 
Contralateral CN and/or PUT uptake was pathologically re-
duced in all patients. 
  MIBG scintigraphy disclosed a pathologically reduced 
myocardial MIBG uptake in 88 of 95 patients. All patients 
with normal MIBG scintigraphy were at Hoehn and Yahr 
stage 1. At each Hoehn and Yahr stage separately, myocar-
dial MIBG uptake correlated significantly with contralateral 
CN and PUT FP-CIT uptake (p < 0.05; Fig. 1). Furthermore, 
there was a significant correlation between MIBG uptake 
and ipsilateral CN and PUT FP-CIT uptake (p < 0.05; Pear-
son´s correlation) at each Hoehn and Yahr stage. Multiple 
regression analysis showed that the correlation CN or PUT 
FP-CIT uptake versus myocardial MIBG uptake were not 
significantly influenced by the factors age, age at disease 
onset, disease duration or UPDRS (p > 0.05; multiple regres-
sion analysis). 
 
Fig. (1). Correlation between putamen FP-CIT SPECT and MIBG 
scintigraphy. Each patient is represented by one symbol (patients 
with Hoehn and Yahr stage 1: yellow triangles, patients H&Y stage 
2: red squares, patients H&Y stages 3 + 4: blue rhombs). 
Controls 
  FP-CIT SPECT (n = 40 values due to bilateral measure-
ment) and MIBG scintigraphy (n = 20) were normal in all 20 
controls. For calculation of correlation between myocardial 
MIBG uptake and striatal FP-CIT uptake we considered the 
CN and PUT tracer uptake each of both sides: there was no 
significant correlation between MIBG uptake versus CN or 
PUT FP-CIT uptake. 
 
DISCUSSION 
  Idiopathic Parkinson´s disease (PD) is defined by the 
neuropathological finding of Lewy bodies (LB) primarily in 
the substantia nigra and other nuclear grays of the brain 
(Turner 1968) [25]. Based on the intracerebral formation of 
LB, Braak et al. (Braak CTR 2004) [26] defined six stages of 
PD. This sequence of cerebral LB degeneration is not ran-
dom but results from the differing vulnerability and suscep-
tibility of cerebral cell types to develop LB (Braak CTR 
2004) [26]. Numerous studies found LB also in extracranial 
organs, especially in the peripheral autonomic nervous sys-
tem: in the sympathetic system (intermediolateral nucleus of 
the thoracic cord and paravertebral sympathetic ganglia), the 
parasympathetic system (dorsal vagal and sacral parasympa-
thetic nuclei; Iwanaga Neurology 1999, Kaufmann Neurol-
ogy 2004, Wakabayashi and Takahashi EN 1997) [5, 6, 9], 
the adrenal medulla, and in the neural plexi innervating the 
gut, heart and pelvis (Edwards Neurology 1992, Micieli NS 
2003, Okada PI 2004) [4, 7, 8]. These numerous histopa-
thological changes at different parts of central and peripheral 
nervous system correlate with common clinical symptoms in 
PD such as constipation, orthostatic hypotension, detrusor 
hyperactivity or seborrhea (Deuschl 1999; Micieli NS 2003) 
[2, 7]. It is quite unclear whether there exists any relation 
between cranial and extracranial LB degeneration in PD. 
Furthermore the question arises whether cranial and extrac-
ranial LB degeneration are induced by the same pathome-
chanisms and thus are coupled in PD. 
  In the present paper we studied whether there exists a 
correlation between the cerebral nigrostriatal dopaminergic 
function and the extracranial sympathetic myocardial func-
tion. We quantified cerebral nigrostriatal dopaminergic 
function with FP-CIT SPECT and extracranial sympathetic 
myocardial function with MIBG scintigraphy. We assumed 
that nigrostriatal dopaminergic function reflects the extent of 
nigral LB degeneration. Accordingly we measured the sym-
pathetic myocardial function as a correlative for severity of 
myocardial sympathetic LB degeneration. Since stage, sever-
ity and duration of PD correlate significantly with reduction 
of nigrostriatal FP-CIT uptake (Benamer MD 2000) [14] and 
myocardial MIBG uptake (Hamada JNNP 2003) [12], we 
studied patients separately after Hoehn and Yahr stage to 
exclude a statistical bias due to the factors disease stage or 
severity. 
  We found a highly significant correlation between cere-
bral caudate nucleus (CN) and putamen (PUT) FP-CIT up-
take versus extracranial myocardial MIBG uptake at all 
Hoehn and Yahr stages. Multiple regression analysis showed 
this significant correlation was not caused or influenced by 
the factors age, age at disease onset, disease duration or 
UPDRS. In the non-parkinsonian control subjects, there was 
no significant correlation between CN/PUT FP-CIT uptake 
versus extracranial myocardial MIBG uptake. This contra-
dicts a physiological coupling of nigrostriatal dopaminergic 
and myocardial sympathetic function and proves that the 
close coupling between nigrostriatal degeneration and myo-
cardial sympathetic degeneration in PD represents a patho-
logical phenomenon. 
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CONCLUSIONS 
  Our data indicate a strongly coupled degeneration of ni-
grostriatal dopaminergic and myocardial sympathetic trans-
mission at early as well as advanced stages of PD. We as-
sume that at least cerebral  nigrostriatal dopaminergic LB 
degeneration and extracranial  myocardial sympathetic LB 
degeneration develop in a coupled manner. Obviously both 
processes are driven by identical or at least similar pathome-
chanisms. Our results give strong evidence that the clinically 
and histopathologically manifest cerebral and extracranial 
degenerative changes in PD do not develop independently 
from each other but develop in a strongly coupled manner. 
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